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Мета. Дослідити ефективність регулювання редокс-залежних механізмів нейропротекції різних 
фармакологічних схем N-ацетилцистеїну (NAC) та мелатоніну (Mel) у головному мозку щурів з 
експериментальним цукровим діабетом 1 типу (ЦД 1). 
Методи. Щури з індукованим ЦД 1 отримували NAC (1,5 г/кг), Mel (10 мг/кг) або їх комбінацію 
(NAC+Mel) протягом 5-ти тижнів. Стан електрон-транспортного ланцюга (ЕТЛ) мітохондрій, 
швидкість генерування супероксидних радикалів (СР), активність nNOS, концентрацію лактоферину, 
«вільного заліза», метгемоглобіну, 8-oxoG в клітинах головного мозку щурів досліджували методом 
електронного парамагнітного резонансу (ЕПР) на комп’ютеризованому ЕПР-спектрометрі РЕ-1307 за 
температури рідкого азоту (Т=77К). 
Результати. Через 7 тижнів після індукції ЦД 1 швидкість генерування СР мітохондріями головного 
мозку щурів з ЦД 1 була значно вищою, а активність нейрональної NO-синтази (nNOS) зниженою, 
порівняно з групою контролю. Було встановлено зменшення активності Комплексу І ЕТЛ мітохондрій 
та зростання рівня 8-oxoG, концентрації «вільного заліза», NO-FeS-білків, концентрації лактоферину 
та MetHb, в тканині головного мозку тварин з ЦД 1. Всі досліджувані фармакологічні схеми сприяли 
достовірному зниженню швидкості генерування СР та відновленню активності nNOS мітохондріями 
головного мозку. Фармакологічна корекції NAC/Mel або NAC+Mel сприяла достовірному зниженню рівня 
8-oxoG та комплексів NO-FeS-білків, нормалізації активності комплексів «вільного заліза» тканини 
головного мозку щурів з ЦД 1. Терапія NAC також сприяла зменшенню рівня MetHb, а комбінована 
терапія NAC+Mel - зменшенню рівня лактоферину головного мозку щурів з ЦД1. 
Висновки. При індукції ЦД 1 типу відбувається пошкодження ЕТЛ мітохондрій продуктами неповного 
розпаду глюкози, що проявляється зниженням синтезу АТФ, підвищенням рівня СР, які генеруються в 
наслідок порушення механізму транспорту електронів. Терапія NAC та Mel чи їх комбінації 
супроводжувалася захистом клітин головного мозку щурів з ЦД 1 від токсичної дії СР, перешкоджаючи 
порушення функцій мітохондрій, що свідчить про нейропротективну дію. NAC та Mel є перспективними 
лікарськими засобами для профілактики та лікування діабетичної нейропатії 
Ключові слова: цукровий діабет, головний мозок, оксидативний стрес, N-ацетилцистеїн, мелатонін, 
мітохондрії, супероксид 
 
1. Introduction 
Diabetes mellitus (DM) is one of the most 
common diseases with a steady tendency to increase, "a 
non-infectious epidemic of the 21st century" [1]. It is 
projected that by 2030 the number of patients will reach 
552 million (9.9 % or 1 diabetes patient in 10 healthy 
adults), and by 2035 – to 592 million (10.1 %) [2]. DM 
is one of the main causes of cerebrovascular 
complications. So, the risk of stroke, in patients with 
diabetes, is 3–4 times higher. In 10 % of cases, vascular 
complications in patients with DM, lead to lethal effects 
[3]. The authors of numerous scientific papers in 
experimental and clinical studies have identified the 
leading role of oxygen and nitrogen radicals in the 
pathogenesis of diabetes and its complications, in 
particular, diabetic encephalopathy [4, 5]. 
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2. Formulation of the problem in a general 
way, the relevance of the theme and its connection 
with important scientific and practical issues 
An important mechanism for the development of 
diabetic encephalopathy is the oxidative stress caused by 
hyperglycemia, which causes excessive formation of 
superoxide radicals (SR) and exhaustion of the 
antioxidant defense system [6]. Strengthening the 
generation of SR initiates the activation of 5 signaling 
pathways, which are involved in the pathogenesis of 
complications of diabetes. These include: increased 
formation of advanced glycation end-products (AGE), 
increased expression of AGE receptors, polyol glucose 
utilization, activation of protein kinase C isoforms, 
hyperactivity of the hexosamine pathological pathway 
[7]. Signal pathways activate apoptosis reactions and 
cause energy depletion, which leads to damage to 
neurons and the development of diabetic encephalopathy 
[8]. The role of autophagy, a dynamic process, which 
plays an important role in the regulation of cellular 
homeostasis by processing macromolecules and 
dysfunctional organelles, as well as various types of 
reactive oxygen species (ROS) [9, 10], is actively studied 
today.  
 
3. Analysis of recent studies and publications in 
which a solution of the problem are described and to 
which the author refers 
The brain cells are particularly susceptible to 
oxidative damage due to the increased oxygen 
metabolism, high lipid content and relative weakness of 
antioxidant defense [11]. Recent research has established 
the leading role of mitochondria in the ischemic injury of 
the brain in the launch of cascade of oxidative, 
morphofunctional neuronal disorders [11, 12]. Induced 
by hyperglycemia, accumulation with mitochondria of 
the ROS leads to disturbance of ion transport, impulse 
generation and conduction, rejection of reuptake of 
mediators (catecholamines, dopamine, serotonin), 
denovo protein synthesis disorder, reprogramming of 
energy-producing reactions, causing a significant 
decrease in energy reserves and loss of neurons [11]. 
Therefore, an important link of the cerebroprotective 
mechanism of action of modern durgs is their 
mitoprotective action.  
To date, the role of N-acetylcysteine (NAC), a 
synthetic drug with antioxidant properties, in the 
treatment of diseases of the central nervous system is 
widely studied [13]. Experimental studies indicate the 
ability of NAC to detect cerebroprotective effects under 
DM conditions [14]. 
Recent studies point to the ability of melatonin to 
influence the functioning of mitochondria, penetrating 
through membranes it stimulates antioxidant enzymes 
such as superoxide dismutase, catalase, glutathione 
peroxidase, glutathione reductase, which contributes to 
increased resistance to oxidative damage [15]. 
 
4. The field of research considering the general 
problem, which is described in the article 
Data on the neuroprotective effect of N-
acetylcysteine and melatonin are very fragmented. The 
NO- and CP-dependent mechanisms of cerebroprotection 
of N-acetylcysteine and melatonin in case of DM 1 have 
not been studied sufficiently.  
 
5. Formulation of goals (tasks) of article 
The aim of the work was to study the 
effectiveness of regulation of redox-dependent 
mechanisms of neuroprotection processes of NAC and 
Mel various pharmacological schemes, in the brain of 
rats with experimental DM 1. 
 
6. Presentation of the main research material 
(methods and objects) with the justification of the 
results 
Experiments were carried out on 35 adult male 
Wistar rats weighing 200–260 g, grown in vivarium of 
the National Medical University named after O.O. 
Bogomolets. All manipulations on animals have been 
carried out in accordance with the Law of Ukraine No. 
3447-ІV "On the protection of animals from cruel 
treatment" and in accordance with the "Directive of the 
European Union of 2010/10/63 of the EU on the 
Protection of vertebrates used for experimental and other 
scientific purposes" [16]. Compliance with the bioethical 
principles, while working with laboratory animals, is 
certified by the expert opinion of the Ethics Committee 
of the NMU named after O.O. Bohomolets (protocol 
№99 dated 12/28/2016). 
Animals were kept in the conditions of 12-hour 
daily regime (8: 00–20: 00 light and 20: 00–8: 00 – dark 
time of day), natural light, at room temperature (19– 
24 °C), relative humidity (50–65 %) in standard plastic 
cages of 3–4 animals. They received a diet of feed mix 
and cooled boiled water as needed. 
Type 1 diabetes mellitus was modeled by 
administration of streptozotocin (STZ) (Sigma, USA) at 
a dose of 50 mg / kg in citrate buffer solution (pH 4.5) 
once intraperitoneally according to guidelines [17]. The 
DM was monitored by blood glucose content, which was 
determined using the One Touch Select Simple Portable 
Meter (LifeScan, USA). After 72 hours, animals with 
persistent hyperglycemia with a peripheral blood glucose 
index higher than 15 mmol / l were taken.  
Animals were divided into 5 groups: 1 – control 
(n=7; intact animals); 2 – DM 1 (n=7; group of model 
animals with streptotrozine DM 1 receiving 0.9 % 
physiological saline per os); 3 – NAC (n=7; group of 
diabetic rats receiving N-acetylcysteine (STADA) at a 
dose of 1.5 g / kg per os); 4 – Mel (n=7; group of diabetic 
rats receiving melatonin (Kyiv Vitamin Factory) at a 
dose of 10 mg / kg per os); 5 – NAC + Mel (n=7; group 
of model animals with streptozotocin DM 1 receiving a 
combination of N-acetylcysteine (1.5 g / kg) and 
melatonin (10 mg / kg)). Doses were selected according 
to literature sources [18, 19].  
The investigational medicinal products were 
administered to experimental animals for 5 weeks, 
started 2 weeks after induction of DM. 
We studied the changes in the functioning of the 
electron transport chain (ETL) of the mitochondria, the 
rate of SR generation, the activity of the neuronal NO 
synthase (nNOS), the concentration of lactoferrin, "free 
iron", methemoglobin (MetHb), and the level of 8-
oxoguanin in rat brain tissue cells. 
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Changes in the functioning of the mitochondria 
ETL were determined by the location of the EPR signals 
(g is the spectroscopic fraction factor), and the amplitude 
of the corresponding signal was measured. The studies 
were carried out by the method of electron paramagnetic 
resonance (EPR) in a low temperature (77 K) of 
biological material stabilization [20]. For this, 500 mg of 
brain tissue was placed in a special mold and frozen in 
liquid nitrogen. The obtained tissue samples were 
investigated in a paramagnetic pure quartz diver on a 
computerized spectrometer RE-1307 with resonator 
H011 at a temperature of liquid nitrogen (77 K). The 
power of the microwave source was 40 mW, the 
modulation frequency was 100 kHz and the amplitude  
10 Gaussian, the receiver's continuous time τ=0.3 sec. As 
a standard of intensity, a specially oriented sample of 
Al2O3 single crystal with a specific concentration of Cr
3+ 
ions was used. The method of double integration 
evaluated the concentration of molecules by comparing 
the intensity of signals in EPR spectra with the intensity 
of the standard. Error in the method of spectrum 
integration and the spread of spectrum reproduction of 
one sample is not more than 3 %. 
The rate of SR generation in the tissues was 
determined by the EPR method at room temperature in a 
paramagnetic clear quartz cell using a spin capture 
TEMPONE-H ("Sigma"). The activity of nNOS was 
determined by the EPR method using SpinTraps 
technology, as the spin trap was used by 
diethylthiocarbamate (Sigma) [21]. 
The molecular marker of oxidative DNA damage 
- 8-oxoguanine (8-oxoG) - was determined by analyzing 
ultraviolet spectra of eluates after their solid phase 
extraction from the brain [22]. 
The concentration of lactoferrin, "free iron", 
MetHb, was investigated by EPR method at a 
temperature of liquid nitrogen (77 K) [21]. 
Statistical data processing was performed using 
variation statistics using the SPSS Statistics (version 
22.0) program using AVONA single-factor analysis of 
variance with the Dunnet criterion for comparison groups 
with control and experimental groups. The normal 
distribution of variables was checked by the Shapiro-
Vilka test. The spot evaluation of the results was 
presented in the form of average values and standard 
error of the mean (X±m). At the critical level of 
significance during the check of statistical hypotheses 
were taken p <0.05. 
The EPR brain specimens of rats with DM 1 and 
intact animals contain the following EPR signals, namely 
g=2.0, which characterizes the level of f 
flavoubisemiquinones in ETL mitochondria; g=2.03 – 
level of formation of NO complexes with FeS proteins in 
ETL mitochondria; g=1.94-activity of the Fe-protein N-2 
in the protein NAD • H-ubiquinone oxidoreductase 
electron transport complex of the respiratory chain of 
mitochondria. 
7 weeks after the induction of DM 1, the rate of 
SR generation (Fig. 1a), in the mitochondria of the brain, 
in the group of animals with DM 1 was significantly 
higher compared with the control (0.93±0.14 nm / g 
tissue • min v 0.15±0.05 nm / g tissue • min, p <0.01). 
The activity of the neuronal NO synthase (nNOS) (Fig. 
1b), the brain of the rats with DM 1, was reduced 
compared to the control group of rats (0.47±0.04 nm / g 
tissue minus 1.2±0.09 nm / g tissue • min, p <0.01). The 
analysis of changes in the rate of SR generation, after  
5 weeks of pharmacotherapy, showed a statistically 
significant decrease compared with the group of diabetes 
mellitus (p <0.05). Thus, the rate of SR generation when 
the NAC was set to 0.75±0.07 nm / g tissue • min. Mel 
treatment caused a decrease in the rate of SR generation 
by 27.96 % (0.67±0.09 nm / g tissue min) and 40.86 % 
(0.55±0.08) combined therapy.  
NAC induced an increase in nNOS activity in the 
mitochondria of the brain cells of diabetic rats  
(0.7±0.05 nm / g tissue minus vs. 0.47±0.04, p<0.01). 
Mel therapy also contributed to an increase in the activity 
of nNOS (0.87±0.1 nm/g tissue • min, p<0.01). The 
combined pharmacotherapy of NAC and Mel contributed 
to the growth of nNOS activity to 0.95±0.05 nm/g tissue 
(min. p<0.01) compared to the DM 1 group without 
treatment. 
The level of 8-oxoG, a marker of oxidative 
damage to nucleic acids in rat brain cells, after 7 weeks 
of induction of DM 1, was significantly higher in 
comparison with the control group (0.61±0.1 nm/g of 
crude tissue versus 0.18±0.06, p<0.01). After 
pharmacological correction of NAC/Mel or NAC+Mel, 
the level 8-oxoG (Fig. 2) was significantly lower in 
comparison with the group receiving the physiological 
solution (p<0.01).  
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a 
 
 
b 
Fig. 1. Influence of N-acetylcysteine (NAC) and melatonin (Mel) on the rate of generation of superoxide radicals and 
nNOS activity in mitochondria of brain cells: a – the rate of generation of superoxide radicals; b – nNOS activity. DM 1 
(rats with diabetes mellitus 1 receiving physiological saline per os); NAC (rats with DM 1, administered NAC at a dose 
of 1.5 g / kg per os); Mel (rats with DM 1 receiving Mel in a dose of 10 mg / kg per os); NAC+Mel (diabetic rats 
receiving NAC and Mel per os combination therapy); control (intact rats). NAC / Mel or NAC+Mel was administered 
within 5 weeks. * in comparison with control, p <0.05; # in comparison with DM 1, p<0.05 
 
 
 
Fig. 2. Changes in the level of 8-oxoG in brain cells of diabetic rats that received a physiological solution and drugs. 
DM 1 (rats with diabetes mellitus 1 receiving physiological saline per os); NAC (rats with DM 1, administered NAC at 
a dose of 1.5 g/kg per os); Mel (rats with DM 1 receiving Mel in a dose of 10 mg/kg per os); NAC+Mel (diabetic rats 
receiving NAC and Mel per os in combination therapy); control (intact rats). NAC / Mel or NAC+Mel were 
administered within 5 weeks. * in comparison with control, p<0.01; # in comparison with DM 1, p<0.01 
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The damaging effect of DM 1 on ETL on the 
mitochondria of rat brain cells was manifested by the 
increase in the level of complexes of NO-FeS proteins 
(Fig. 3, a) to 0.097±0.007 c.u., when compared with the 
control group – 0.05±0.02 (p<0.05). Increasing the level 
of the complex indicates the interaction of NO, 
synthesized nNOS, with FeS – proteins of mitochondria 
with a violation of the oxidative phosphorylation process. 
NAC/Mel or NAC+Mel therapy reduced the level of 
complexes of NO-FeS proteins, but the difference was 
not statistically significant (p>0.05). 
The activity of the Complex I ETL of the rat 
mitochondria of the brain (Fig. 3, b) with DM 1 was 
0.125±0.011 c. u., which is 4.6 times lower than the 
control values – 0.58±0.07 c.u. (p<0.05). NAC therapy 
increased the activity of Complex I ETL mitochondria to 
0.2±0.058 c.u. (in 1.6 times more, in comparison with the 
group of DM 1 (p<0.05)).  
Pharmacorrection of Mel and NAC+Mel also 
gave a positive result (0.22±0.009 doses and 0.25±0.006 
doses respectively) (p<0.05).  
In cells of intact animals, the level of the ESR 
signal of the "free iron" complexes ("FI") was recorded 
within 0.08±0.004 c. u., whereas in the brain cells of 
animals with DM 1 under the same conditions – 
1.357±0.176 c. u. (p<0.01) (Fig. 4). Thus, for DM 1 there 
is an increase in oxidative processes due to the 
accumulation of "FI" complexes, increase in their content 
in the intercellular matrix, and the formation of an 
oxidizing phenotype. The introduction of investigated 
drugs contributed to the reduction of "FI" complexes 
(p<0.01). The values close to the control were observed 
in the group of animals receiving NAC (0.158±0.008 c. 
u.). In the brain of animals receiving Mel, the levels of 
the "FI" complexes were 2.1 times smaller (0.68±0.11 c. 
u.), and in animals receiving the combination therapy 
NAC+Mel – 3.7 times (0.325±0.034 c. u.).  
 
 
a 
 
 
b 
Fig. 3. Influence of N-acetylcysteine (NAC) and melatonin (Mel) on the level of complexes of NO-FeS-proteins and 
activity of complex I ETL of mitochondria of rat cell cultures: a – level of complexes of NO-FeS proteins; b – activity 
of complex I ETL mitochondria. DM 1 (rats with diabetes mellitus 1 receiving physiological saline per os); NAC (rats 
with DM 1, administered NAC at a dose of 1.5 g/kg per os); Mel (rats with DM 1 receiving Mel in a dose of 10 mg/kg 
per os); NAC+Mel (diabetic rats receiving NAC and Mel per os combination therapy); control (intact rats). NAC/Mel or 
NAC+Mel were administered within 5 weeks; * in comparison with control, p<0,05;  
# in comparison with DM 1, p<0.05 
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Fig. 4. Changes in the concentration of "free iron" complexes in brain cells of diabetic rats that received a physiological 
solution and medicinal substances. DM 1 (rats with DM 1 receiving physiological saline per os); NAC (rats with DM 1, 
administered NAC at a dose of 1.5 g/kg per os); Mel (rats with DM 1, receiving Mel at a dose of 10 mg/kg per os); 
NAC+Mel (diabetic rats receiving NAC and Mel per os combination therapy); control (intact rats). NAC/Mel or 
NAC+Mel were administered within 5 weeks; * in comparison with control, p<0,05; # in comparison with DM 1, 
p<0.05 
 
It was also found that the level of flavou- 
bisemiquinones in the brain of DM 1 animals receiving a 
physiological solution was 0.14±0.009 c. u., whereas in 
the control group it was 0.35±0.05 c. u. (p<0.05). Only 
NAC+Mel combination therapy had a statistically 
significant increase in the level of flavoubisemiquinones 
(0.28±0.008 c. u.). 
In the brain cells of rats with DM 1, the 
concentration of lactoferrin (LF) was 0.16±0.019 spins/g 
of crude tissue, respectively, 14.8 times higher than the 
content of LF in the brain cells of intact rats, which was 
0.078±0.01 spins/g of raw tissue (p<0.05). Combined 
NAC+Mel therapy, unlike monotherapy, reduced the 
level of LF of the brain of rats from DM 1 (0.09±0.011 
spins/g of crude tissue, p<0.05). 
In the cages of the brain of rats with DM 1, the 
level of MetHb was 9.6 times higher than the control 
group (0.192±0.011 vs. 0.020±0.002 c. u., p<0.05). NAC 
therapy contributed to a significant decrease in MetHb 
level in the brain of rats with DM 1 (0.120±0.01 c. u., 
p<0.05). Mel in monotherapy and in combination with 
NAC also reduced the MetHb level, but the values were 
not statistically significant (0.155±0.015 and 
0.148±0.013 c. u., p>0.05). 
According to literary sources, hyperglycemia 
leads to a disturbance of the ETC function of 
mitochondria and causes an increase in the generation of 
ROS. Since mitochondria are the main source of ROS, 
oxidative stress, induced by disturbances of mitochon- 
drial functions, also contributes to the development of 
diabetic neuropathy [23]. Neurons use oxidative 
phosphorylation to meet energy needs, so changing the 
functioning of mitochondria leads to energy shortages 
and deaths of neurons. Violation of the functions of the 
neurons leads to an increase in the level of ROS, due to 
the leakage of electrons from ETC [24]. Under 
pathological conditions, with high glucose content inside 
the cell, more NADH and FADH2 are formed in the 
Krebs cycle and more electrons are transmitted to the 
electron transport chain. As a result, the intermembrane 
proton gradient increases to a certain limit after which 
further transport of electrons to complex III is blocked, 
turning the electrons back to the Q complex, which 
transports them one by one to molecular oxygen, thus 
forming the superoxide radical [7]. CP cause damage to 
mitochondrial DNA and proteins, which results in a 
breach of ETC and an additional increase in the amount 
of SR. In addition, NO can interact with CP, which 
results in the formation of peroxynitrite that can induce 
lipid peroxidation and activate the cascade of events that 
results in DNA damage [25]. 
The obtained results indicate that the 
administration of various pharmacological schemes of 
NAC, Mel or their combination for 5 weeks to rats with 
streptozotocin DM 1 promotes the protection of 
mitochondria from oxidative damage. Pharmacotherapy 
caused a decrease in the rate of generation of SR 
(p<0.05) and an increase in the activity of nNOS 
(p<0.01). Medicinal products helped to normalize the 
functioning of ETC mitochondria.  
Mel plays an important role in the regulation of 
mitochondrial homeostasis. It reduces the generation of 
nitric oxide in mitochondria and supports the 
bioenergetic functions of cells. Mel is activator of 
antioxidant enzymes, in particular catalase, superoxide 
dismutase, glutathione reductase, and lipoxygenase 
inhibitor. It increases resistance to oxidative damage by 
stabilizing microsomal membranes [26]. Introduction of 
Mel in rats with experimental DM 2 contributed to 
improving the functioning of liver mitochondria due to 
increased activity of mitochondrial citrate synthase 
(p<0.001), complex IV ETL (p<0.05), normalization of 
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phosphorylation coefficient (p<0.05). The authors note 
that therapy also led to an increase in the synthesis of 
ATP (p<0.05) [27]. Another study showed that Mel in a 
dose of 10 mg/kg contributes to the protection of 
mitochondria of adipose tissue, in experimental rats DM 
2, from oxidative damage [28]. 
Introduction of NAC to streptozotocin-induced 
DM 1 rats at a dose of 1.5 g/kg for 4 weeks contributed 
to a decrease in the rate of SR generation and an increase 
in NO (p<0.01) by aortic mitochondria. It has been 
shown that in the liver, NAC also increased the rate of 
generation of CP while NO was reduced [7]. 
 
7. Conclusions from the conducted research 
and prospects for further development of this field 
1. The rate of SR generation, the mitochondria of 
the brain cells of untreated rats with DM 1, was 
significantly higher compared to the control group 
(0.93±0.14 nm/g tissue minus vs 0.15±0.05 nm/g tissue • 
min, p<0.01). 
2. There was a violation of the synthesis of nNOS 
in rat brain tissue from DM 1, which may be due to 
damage to NO synthase, or as a result of the interaction 
of NO with superoxide radicals, which leads to the 
formation of peroxynitrite. There was an increase in the 
formation of complexes of NO-FeS proteins 
(0.097±0.007 c. u., in the control – 0.05±0.02, p<0.05) 
indicating the interaction of NO synthesized by nNOS 
with FeS-proteins of mitochondria with process 
disturbance oxidative phosphorylation. A decrease in the 
activity of the Complex I ETL mitochondria was 
detected (0, 125±0.011 c. u., while in the control it was 
0.58±0.07 c. u., p<0.05). 
3. Modeling of DM 1 in rats was accompanied by 
an increase in the level of 8-hunting G-marker oxidative 
damage to nucleic acids (0.61±0.1 nm/day/g vs. 
0.18±0.06, p<0.01), activity of complexes "Free iron" 
(1.357±0.176 c. u., while in the control – 0,08±0,04 c. u., 
p<0,01) concentration of lactoferrin (0.16±0.019 spins/g of 
raw tissue against 0.078±0.01 spins/g of raw tissue <0,05) 
and MetHb (0.192±0.011 versus 0.020±0.002 rpm, 
p<0.05), in the brain tissue. 
4. The administration of NAC, Mel, and their 
combination in rats with experimental DM 1 contributed 
to protecting the cells of the brain relative to the toxic 
effect of SR (the rate of SR generation was  
0.75±0.07 nm/g tissue • min, 0.67±0.09 nm/g tissue • 
min, and 0.55±0.08 nm/g tissue • min, p<0.05). The 
protective effect of the drugs was manifested by the 
growth of nNOS activity (0.7±0.05, 0.87±0.1 and 
0.95±0.05 nm/g tissue • min, respectively, p<0.01), 
preventing the progression of damage to neurons. 
5. Pharmacological correction of NAC/Mel or 
NAC + Mel contributed to a significant decrease in the 
level of 8-oxoG (0.39±0.06, 0.35±0.07 and  
0.3±0.04 nm/g of crude tissue, compared with DM  
1 group without treatment – 0.61±0.1, p<0.01), increase 
in the activity of the complex I ETL mitochondria 
(0.2±0.058, 0.22±0.009 and 0.25±0.006 c. u., p<0.05) 
normalization of the activity of the "FI" complexes of the 
brain tissue of rats from DM 1 (0.158±0.008, 0.682±0.11 
and 0.325±0.034 c. u., p<0.05). Therapy also contributed 
to a reliable NAC a decrease in the level of MetHb 
(0.192±0.011 units, p<0.05) and the combination therapy 
NAC+Mel, in contrast to monotherapy, contributed to a 
decrease in the molar LF of the brain of rats from DM 1 
(0.09±0.11 spins/g of raw tissue, p<0.05). 
6. NAC/Mel in monotherapy and combination 
therapy are promising drugs for the prevention and 
treatment of diabetic neuropathy.  
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